Lifyorli Kit
FDA Label NDC 76346-550

LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies (14)].

LIFYORLI

Follow LIFYORLI dosing instructions provided on the blister card.

Take LIFYORLI with food.

Swallow capsules whole. Do not crush, chew, dissolve, or split the capsules.

If a dose of LIFYORLI is missed by less than 12 hours, take the missed dose. If a dose of LIFYORLI is missed by 12 hours or more, skip the missed dose and take the next dose at the regularly scheduled time. Do not take 2 doses at the same time to make up for a missed dose.

If vomiting occurs after taking LIFYORLI, do not take an additional dose.

Nab-Paclitaxel

The recommended dosage and dosage modifications for nab-paclitaxel when administered in combination with LIFYORLI differ from those for other nab-paclitaxel indications [see Dosage and Administration (2.2 and 2.3) and Clinical Studies (14)].

Do not substitute with other paclitaxel formulations.

Strong CYP3A Inducers

Avoid coadministration of LIFYORLI plus nab-paclitaxel with strong CYP3A inducers.

Both relacorilant and paclitaxel are CYP3A substrates. Coadministration of strong CYP3A inducers can decrease concentrations of relacorilant and paclitaxel, which may reduce their effectiveness [see Clinical Pharmacology (12.3)].

CYP2C8 Inducers and Moderate CYP3A Inducers

Monitor for reduced effectiveness of LIFYORLI plus nab-paclitaxel with CYP2C8 inducers and moderate CYP3A inducers.

Paclitaxel is a substrate of CYP2C8 and CYP3A and relacorilant is a CYP3A substrate. Coadministration of CYP2C8 inducers and moderate CYP3A inducers can decrease concentrations of paclitaxel and relacorilant, which may reduce their effectiveness.

CYP2C8 Inhibitors

Monitor for increased adverse reactions and modify the dosage for adverse reactions as recommended [see Dosage and Administration (2.3)].

Paclitaxel is a substrate of CYP2C8. Coadministration of CYP2C8 inhibitors may increase concentrations of paclitaxel, which may increase the risk of adverse reactions.

CYP3A Substrates

Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP3A substrates.

Relacorilant is a strong CYP3A inhibitor. Relacorilant increases exposure of CYP3A substrates [see Clinical Pharmacology (12.3)], which may increase the risk for adverse reactions related to these substrates.

Certain CYP2C8 Substrates

Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP2C8 substrates where minimal concentration changes may lead to reduced effectiveness. Relacorilant is a weak CYP2C8 inducer. Relacorilant decreases exposure of CYP2C8 substrates [see Clinical Pharmacology (12.3)], which may decrease the effectiveness related to these substrates.

Risk Summary

LIFYORLI is used in combination with nab-paclitaxel. Refer to the Prescribing Information of nab-paclitaxel for pregnancy information.

Based on findings in animals, LIFYORLI can cause fetal harm when administered to a pregnant woman. There are no available data on relacorilant use in pregnant women to inform drug-associated risk. In animal embryo-fetal development studies, oral administration of relacorilant to pregnant rabbits during the period of organogenesis resulted in embryo-fetal mortality and structural abnormalities at maternal doses of ≥ 10 mg/kg/day (0.6 times the human exposure based on area under the curve (AUC) at the recommended dose). Oral administration of relacorilant to pregnant rats during the period of organogenesis did not result in fetal malformations [see Data].

Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is between 2 to 4% and 15 to 20%, respectively.

Data

Animal Data

Relacorilant is a partial agonist of the glucocorticoid receptor in rats. In an embryo-fetal development study, relacorilant was administered to pregnant rats at oral doses of 1, 2.5, and 10 mg/kg/day during the period of organogenesis. Maternal toxicity (decreased body weight and food consumption) was observed at a dose of 10 mg/kg/day (3.8 times the human exposure based on AUC at the recommended dose). No developmental toxicity was noted at doses up to 10 mg/kg/day.

In an embryo-fetal development study, relacorilant administered to pregnant rabbits at oral doses of 1, 3, and 10 mg/kg/day during the period of organogenesis resulted in embryo-fetal mortality (increased post-implantation loss, fetal resorptions, and a decrease in litter size) at 10 mg/kg/day (0.6 times the human exposure based on AUC at the recommended dose). Fetal malformations (abnormal flexure of the forepaw, microcephaly, malrotated hindlimbs, absent interparietal bone, and fused sternebra in sternum) were observed at a dose of 10 mg/kg/day (0.6 times the human exposure based on AUC at the recommended dose). Additional adverse effects included skeletal variations of bipartite interparietal bone of the skull observed at doses ≥ 1 mg/kg/day (lower than the human exposure based on AUC at the recommended dose).

Risk Summary

LIFYORLI is used in combination with nab-paclitaxel. Refer to the Prescribing Information of nab-paclitaxel for lactation information.

There are no data on the presence of relacorilant or its metabolites in animal or human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with LIFYORLI and for one week after the last dose.

Pregnancy Testing

Verify pregnancy status in women of reproductive potential prior to initiating LIFYORLI.

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with LIFYORLI and for 1 week after the last dose.

Males

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with LIFYORLI and for 1 week after the last dose.

Exposure-Response Relationships

Relacorilant exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized.

Cardiac Electrophysiology

At 3.8 times the mean maximal relacorilant concentration of the recommended dosage, clinically significant QTc interval prolongation was not observed.

Absorption

Relacorilant median (min, max) time to maximum plasma concentration (T_max) is 2.5 hours (1.2, 5.5).

Effect of Food

Relacorilant C_max increased 1.7-fold, AUC increased 2-fold, and T_max was delayed 0.5 hours following administration with a low-fat meal (approximately 400 to 500 calories, 25% fat content).

Relacorilant C_max increased 1.9-fold, AUC increased 2.4-fold, and T_max was delayed 0.25 hours following administration with a high-fat meal (approximately 800 to 1,000 calories, 50% fat content).

Distribution

Relacorilant apparent volume of distribution (V_z/F) is 2490 (54%) L after a single 150 mg dose under fasted conditions. Protein binding of relacorilant in human plasma is >99% in vitro.

Elimination

Relacorilant terminal half-life is 27 (30%) hours with an apparent total clearance of 52 (69%) L/h under fasted conditions.

Metabolism

Relacorilant is primarily metabolized by cytosolic reductases and CYP3A. An active metabolite, CORT125295, with functional activity approximately 5-fold lower than relacorilant, represents 75% of the parent AUC.

Excretion

After a single oral dose of radiolabeled relacorilant 250 mg to healthy participants, about 73% (< 1% unchanged) of the dose was recovered in feces and 17% (< 2% unchanged) in urine.

Specific Populations

No clinically significant differences in the pharmacokinetics of relacorilant were observed based on age (26 to 85 years), body weight (35 to 128 kg), race (White [81%], Asian [9%]), ethnicity (Non-Hispanic [93%], Hispanic [7%]), CLcr 30 to <90 mL/min, or mild hepatic impairment (total bilirubin > ULN to ≤ 1.5 × ULN or AST > ULN and total bilirubin ≤ ULN).

The effect of CLcr <30 mL/min or end-stage renal disease undergoing hemodialysis or severe hepatic impairment (total bilirubin > 3 to 10 × ULN and any AST) on the pharmacokinetics of relacorilant is unknown.

Patients with Hepatic Impairment

Relacorilant AUC increased 1.3-fold in participants with moderate hepatic impairment (Child-Pugh Class B).

Drug Interaction Studies

Clinical Studies

Nab-paclitaxel: Dose-normalized paclitaxel (CYP2C8 and CYP3A4 substrate) C_max increased 2-fold and dose-normalized AUC increased 1.7-fold following coadministration of nab-paclitaxel with LIFYORLI 150 mg.

No clinically significant differences in the pharmacokinetics of relacorilant were observed when given in combination with nab-paclitaxel.

Strong CYP3A Inhibitors: Relacorilant (300 mg once daily for 10 days under fasted conditions) steady state C_max increased 1.2-fold and steady state AUC increased 1.5-fold following coadministration of itraconazole (strong CYP3A inhibitor) 200 mg once daily for 10 days.

CYP3A Substrates: Midazolam (CYP3A substrate) C_max increased 3.1-fold and AUC increased 8.9-fold following coadministration of LIFYORLI 350 mg under fasted conditions (1.8 times the relacorilant exposure at the recommended dosage) once daily for 10 days.

CYP2C8 Substrates: Pioglitazone (CYP2C8 substrate) C_max decreased to 78% and AUC to 75% following coadministration of LIFYORLI 350 mg under fasted conditions (1.8 times the relacorilant exposure at the recommended dosage) once daily for 11 days.

Other Drugs: No clinically significant differences in the pharmacokinetics of the following drugs were observed when used concomitantly with relacorilant: metoprolol (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), or dabigatran etexilate (P-gp).

In Vitro Studies

CYP450 Enzymes: Relacorilant and CORT125295 are inducers of CYP1A2.

Transporter Systems: Relacorilant and CORT125295 are inhibitors of BCRP.

Carcinogenesis

In a 6-month carcinogenicity study, transgenic rasH2 mice were orally administered up to 100 mg/kg/day relacorilant. In a 2-year carcinogenicity study, rats were orally administered up to 10 mg/kg/day in male rats (1.3 times the human exposure based on AUC at the recommended dose) and 3 mg/kg/day in female rats (0.7 times the human exposure based on AUC at the recommended dose). There was no evidence of relacorilant-induced carcinogenicity in either study.

Mutagenesis

Relacorilant was not genotoxic in the bacterial reverse mutation (Ames) assay, an in vitro human lymphocyte micronucleus assay, or an in vivo micronucleus assay in rats.

Impairment of Fertility

In a fertility study, relacorilant was administered orally to male rats prior to and throughout mating and to female rats prior to mating and up to the implantation day (gestation day 7). Relacorilant had no effect on fertility or reproductive function in male or female rats at doses up to 40 mg/kg/day (≥4.5 times the human exposure based on AUC at the recommended dose).

How Supplied

LIFYORLI is available as soft gelatin capsules containing 25 mg or 100 mg of relacorilant.

LIFYORLI 25 mg are opaque dark brown, oval soft gelatin capsules with “CR25” printed in black.

LIFYORLI 100 mg are opaque yellow, oblong soft gelatin capsules with “CR100” printed in black.

LIFYORLI capsules are supplied as follows:

Neutropenia and Severe Infections

Inform patients about the risk of neutropenia and infection. Instruct patients to immediately report any fever or symptoms of infection to their healthcare provider [see Warnings and Precautions (5.1)].

Adrenal Insufficiency

Inform patients that LIFYORLI can cause adrenal insufficiency, a potentially life-threatening condition. Advise patients to immediately report signs or symptoms of adrenal insufficiency to their healthcare provider [see Warnings and Precautions (5.2)].

Exacerbation of Conditions Treated with Glucocorticoids

Advise patients who require chronic or frequent use of glucocorticoids that glucocorticoids may be less effective and to contact their healthcare provider for any worsening symptoms during concomitant use [see Warnings and Precautions (5.3)].

Embryo-Fetal Toxicity

Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

Advise females to inform their healthcare provider of a known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during treatment with LIFYORLI and for 1 week after the last dose.

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with LIFYORLI and for 1 week after the last dose [see Warnings and Precautions (5.4) and Use in Specific Population (8.1, 8.3)].

Lactation

Advise women not to breastfeed during treatment with LIFYORLI and for 1 week after the last dose [see Use in Specific Populations (8.2)].

Administration

Advise patients to follow the LIFYORLI dosing instructions on the blister card. Advise patients to take LIFYORLI with food, how to make up a missed dose, and to swallow capsules whole and to not crush, chew, dissolve or split the capsules [see Dosage and Administration (2.1, 2.2)].

Manufactured for:
Corcept Therapeutics Incorporated
Redwood City, CA 94065

LIFYORLI^TM is a trademark of Corcept Therapeutics Incorporated.
Copyright 2026 Corcept Therapeutics Incorporated. All rights reserved.
USPI-220641-v01 03/2026

The recommended dosage of LIFYORLI is 150 mg orally once on the day before, the day of, and the day after each nab-paclitaxel infusion until disease progression or unacceptable toxicity.

The recommended dosage for nab-paclitaxel is 80 mg/m² administered as an intravenous infusion on Days 1, 8 and 15 of each 28-day cycle until disease progression or unacceptable toxicity [see Clinical Pharmacology (12.3), Clinical Studies (14)]. Refer to the Prescribing Information for nab-paclitaxel for administration.

Dose reduction levels are summarized in Table 1 and Table 2.

The recommended dosage modifications for adverse reactions are provided in Tables 3 and 4. Interrupt or discontinue LIFYORLI whenever nab-paclitaxel is interrupted or discontinued.

Capsules:

• 25 mg: opaque dark brown, oval soft gelatin capsules with “CR25” printed in black.
• 100 mg: opaque yellow, oblong soft gelatin capsules with “CR100” printed in black.

LIFYORLI is contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes (e.g., immunosuppression after organ transplantation) because LIFYORLI antagonizes the effect of glucocorticoids [see Warnings and Precautions (5.3)].

LIFYORLI in combination with nab-paclitaxel can cause neutropenia, including febrile neutropenia and severe infections.

In ROSELLA, decreased neutrophil count occurred in 74% of patients treated with LIFYORLI in combination with nab-paclitaxel, 30% Grade 3, 15% Grade 4, and 3.7% febrile neutropenia. The median time to onset of neutropenia was 15 days (range: 8 to 329). Instances of neutropenia were temporally associated with infection in 16% of patients. There was one fatal event of septic shock with febrile neutropenia. Thirty-eight percent of patients initiated granulocyte colony-stimulating factor (G-CSF) during the first or second cycle of therapy.

Monitor complete blood counts prior to each weekly treatment with LIFYORLI in combination with nab-paclitaxel and as clinically indicated. Based on the severity of neutropenia, delay, reduce dose or permanently discontinue LIFYORLI in combination with nab-paclitaxel. Consider short-acting G-CSF administration as applicable [see Dosage and Administration (2.3)]. Consider the possibility of concurrent adrenal insufficiency, particularly in the setting of serious infection [see Warnings and Precautions (5.2)]. Inform patients to promptly report any episodes of fever to their healthcare provider.

LIFYORLI is a reversible glucocorticoid receptor antagonist and can cause adrenal insufficiency. Adrenal insufficiency can occur at any time during treatment with LIFYORLI. The risk of adrenal insufficiency is increased in situations of stress, such as acute illness, infection, or surgery. Consider whether supplemental glucocorticoids are required in the perioperative period in patients who have received LIFYORLI within 30 days of surgery.

Monitor patients receiving LIFYORLI for signs and symptoms of adrenal insufficiency. Serum cortisol levels do not provide an accurate assessment of adrenal insufficiency in patients receiving LIFYORLI. Withhold LIFYORLI and administer glucocorticoid therapy if adrenal insufficiency is suspected. High doses of supplemental glucocorticoids may be needed to overcome the glucocorticoid receptor antagonism produced by LIFYORLI. When deciding on the duration of glucocorticoid treatment, consider the long half-life of relacorilant (27.5 hours) and that glucocorticoid receptor antagonism may occur for up to 6 days after the last dose of LIFYORLI [see Clinical Pharmacology (12.3)]. After resolution of adrenal insufficiency, resume previous dose, reduce dose or permanently discontinue LIFYORLI based on severity [see Dosage and Administration (2.3)].

Educate patients on the symptoms associated with adrenal insufficiency and advise them to contact a healthcare provider if they occur.

Use of LIFYORLI in patients who are taking systemic glucocorticoids for other conditions (e.g., autoimmune disorders) may exacerbate these conditions. LIFYORLI is a glucocorticoid receptor antagonist which may make systemic glucocorticoids less effective. Similarly, coadministration of systemic glucocorticoids may make LIFYORLI less effective. Monitor patients for reduced effectiveness of LIFYORLI and glucocorticoids in patients receiving both [see Drug Interactions (7.3)]. Patients who require chronic or frequent use of glucocorticoids were excluded from clinical trials of LIFYORLI in combination with nab-paclitaxel.

LIFYORLI is contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes, [see Contraindications (4)].

Based on data from animal studies, LIFYORLI can cause fetal harm when administered to a pregnant woman. Oral administration of relacorilant to pregnant rabbits resulted in adverse developmental outcomes, including embryo-fetal mortality.

Advise pregnant women of the potential risk to a fetus. Verify pregnancy status of females of reproductive potential prior to initiating LIFYORLI treatment. Advise females of reproductive potential to use effective contraception during treatment with LIFYORLI and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with LIFYORLI and for 1 week after the last dose [see Use in Specific Populations (8.1, 8.3)].

The following adverse reactions are discussed in more detail in other sections of the labeling:

• Neutropenia and Severe Infections [see Warnings and Precautions (5.1)].
• Adrenal Insufficiency [see Warnings and Precautions (5.2)]
• Exacerbation of Conditions Treated with Glucocorticoids [see Warnings and Precautions (5.3)].

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of LIFYORLI in combination with nab-paclitaxel was evaluated in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in ROSELLA [see Clinical Studies (14)].

Patients received LIFYORLI (150 mg orally on the day before, the day of, and the day after each administration of nab-paclitaxel 80 mg/m² intravenous infusion on Days 1, 8 and 15 of each 28-day cycle (n=188) or nab-paclitaxel 100 mg/m² intravenous infusion (n=190) until disease progression or unacceptable toxicity. LIFYORLI dosing was interrupted whenever nab-paclitaxel was interrupted. The median duration of LIFYORLI treatment was 4.7 months (range: 0.2 to 24).

Serious adverse reactions occurred in 35% of patients who received LIFYORLI in combination with nab-paclitaxel. Serious adverse reactions in ≥2% of patients were neutropenia (4%), pneumonia (3.2%), pleural effusion (3.2%), febrile neutropenia (2.1%), and fatigue (2.1%). Fatal adverse reactions occurred in 2.1% of patients who received LIFYORLI in combination with nab-paclitaxel including septic shock (0.5%), cardiac arrest (0.5%), ischemic stroke (0.5%), and intestinal perforation (0.5%).

Permanent discontinuation of LIFYORLI in combination with nab-paclitaxel due to adverse reactions occurred in 9% of patients. The adverse reaction which resulted in permanent discontinuation of LIFYORLI in >2% of patients was intestinal obstruction (2.6%).

Dosage interruptions of LIFYORLI due to an adverse reaction occurred in 72% of patients. Adverse reactions which required dosage interruptions of LIFYORLI in combination with nab-paclitaxel in ≥5% of patients included neutropenia (44%), anemia (12%), and fatigue (7%).

Dose reductions of LIFYORLI due to an adverse reaction occurred in 7.4% of patients and dose reductions of nab-paclitaxel occurred in 48% of patients. Adverse reactions which required dose reductions of LIFYORLI included fatigue (1.6%), decreased appetite (1.2%), abdominal pain (0.5%), neutropenia (0.5%), edema (0.5%), and sciatica (0.5%).

The most common (>20%) adverse reactions, including laboratory abnormalities, were decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.

Table 5 and 6 summarize adverse reactions and laboratory abnormalities, respectively, occurring in ≥10% of patients who received LIFYORLI in combination with nab-paclitaxel in ROSELLA.

Clinically relevant adverse reactions occurring in <10% of patients who received LIFYORLI in combination with nab-paclitaxel in ROSELLA included dry eye (8.5%), hypotension (8.5%), hypertension (4.8%), acute kidney injury (4.3%), febrile neutropenia (3.7%), and syncope (2.7%).

LIFYORLI is contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes (e.g., immunosuppression in organ transplantation) [see Contraindications (4)].

Avoid coadministration in patients with other medical conditions requiring systemic glucocorticoids when possible. If coadministration cannot be avoided, monitor patients for reduced effectiveness of LIFYORLI and glucocorticoids.

LIFYORLI is a glucocorticoid receptor antagonist, which may make systemic glucocorticoids less effective. Coadministration of systemic glucocorticoids may make LIFYORLI less effective.

LIFYORLI is used in combination with nab-paclitaxel. Refer to the Prescribing Information of nab-paclitaxel for contraception and infertility information.

LIFYORLI can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

The safety and effectiveness of LIFYORLI in pediatric patients has not been established.

Of the 188 patients with platinum-resistant epithelial ovarian cancer who received LIFYORLI, 38% were 65 years or older and 9.6% were 75 years or older. A higher incidence of grade 3-4 adverse events and dosage modification occurred in patients 65 years or older when compared to younger adult patients. No overall differences in effectiveness were observed between patients in ≥65 years of age and younger patients.

Avoid LIFYORLI in combination with nab-paclitaxel in patients with moderate or severe hepatic impairment (total bilirubin >1.5 to 10x ULN and any AST) because of the potential for increased relacorilant and paclitaxel exposures [see Clinical Pharmacology (12.3)].

LIFYORLI (relacorilant) is a glucocorticoid receptor antagonist antineoplastic agent.

Relacorilant chemical names:

• (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-trifluoromethyl)(pyridin-2-yl)methanone
• [(4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl][4-(trifluoromethyl)pyridin-2-yl]methanone

The molecular formula is C₂₇H₂₂F₄N₆O₃S and the molecular weight is 586.57 g/mol. The chemical structure of relacorilant is:



Chemical Structure Of Relacorilant (Rel04 0002 01)

Relacorilant is an off-white to light yellow solid that is practically insoluble in aqueous media.

LIFYORLI capsules for oral use are supplied as immediate release, printed, soft gelatin capsules containing 25 mg or 100 mg of relacorilant. Each capsule contains the following excipients: butylated hydroxytoluene, lauroyl polyoxyl-32 glycerides, and propylene glycol caprylate. The capsule shell for the 25 mg strength contains black iron oxide, gelatin, red iron oxide, sorbitol special glycerin blend, titanium dioxide, and yellow iron oxide. The capsule shell for the 100 mg strength contains gelatin, sorbitol special glycerin blend, titanium dioxide, and yellow iron oxide. The printing ink contains ammonium hydroxide, black iron oxide, ethanol, ethyl acetate, isopropyl alcohol, macrogol/polyethylene glycol, polyvinyl acetate phthalate, propylene glycol, and purified water.

Relacorilant is a reversible glucocorticoid receptor (GR) antagonist. In functional in vitro assays with the mineralocorticoid receptor, relacorilant showed no agonist or antagonist activity. In human cell-line derived xenograft models, relacorilant enhanced apoptosis and antitumor activity when administered with paclitaxel.

Cortisol binding to the GR is immunosuppressive, decreasing secretion of pro‑inflammatory cytokines. GR antagonism may indirectly activate the immune system; relacorilant inhibited the cortisol-induced reduction of tumor necrosis factor alpha and interferon gamma in stimulated peripheral blood mononuclear cells.

Relacorilant pharmacokinetics were observed in adult patients at the approved recommended dosage and are presented as mean (CV%), unless otherwise specified. Relacorilant maximum concentration (C_max) is 720 (68%) ng/mL and systemic exposure (AUC) is 5,686 (84%) ng*h/mL following the third consecutive daily dose.

The efficacy of LIFYORLI in combination with nab-paclitaxel was evaluated in ROSELLA (NCT05257408), a multicenter, open-label, active-controlled, randomized, two-arm, trial in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients were permitted to receive up to three prior lines of systemic therapy and prior bevacizumab was required. The trial excluded patients who required chronic or frequent use of glucocorticoids.

A total of 381 patients were randomized (1:1) to receive:

• LIFYORLI 150 mg orally the day before, the day of, and the day after administration of nab-paclitaxel 80 mg/m² intravenous infusion on Days 1, 8 and 15 of each 28-day cycle (188)
  or
• nab-paclitaxel 100 mg/m² intravenous infusion on Days 1, 8 and 15 of each 28-day cycle (193)

Treatment was administered until disease progression or unacceptable toxicity. Tumor response assessments occurred every 8 weeks for the first 40 weeks and every 12 weeks thereafter. Randomization was stratified by the following factors: number of prior lines of therapy (1 vs. >1) and region (North America vs. Europe vs. Korea/Australia/Latin America).

The major efficacy outcome measures were progression-free survival (PFS) assessed by blinded independent central review (BICR) and overall survival (OS). PFS was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

The median age was 62 years (range: 26 to 86); 71% were White, 13% were Asian, 1.3% were Black or African American, and 13% did not have race reported. Nine percent of patients were Hispanic or Latino, 76% were non-Hispanic, and 15% had ethnicity not reported or unknown. Nearly all patients had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 (69%) or 1 (30%). Nine percent of patients had received 1 prior line of systemic therapy, 48% of patients had received 2 prior lines of systemic therapy, and 44% of patients had received 3 prior lines of systemic therapy. Thirty-nine percent of patients received prior systemic therapy for platinum-resistant disease. All patients received prior bevacizumab, 99.5% had received a prior taxane (19% in the last line of therapy and 4% in the platinum-resistant setting) and 61% had received a prior PARP inhibitor. Of patients who had received a prior PARP inhibitor, 78% had radiographic progression while receiving the PARP inhibitor.

LIFYORLI demonstrated a statistically significant improvement in PFS and OS for patients randomized to LIFYORLI in combination with nab-paclitaxel compared to nab-paclitaxel monotherapy.

Efficacy results for ROSELLA are summarized in Table 7, Figure 1 and Figure 2.

Table 7: Efficacy Results in ROSELLA

BICR = Blinded Independent Central Review; CI = Confidence Interval
a Results at the pre-specified final PFS analysis.
b Based on the stratified Cox proportional hazard model.
c Two-sided p-value based on stratified log-rank test (compared to a significance level of 0.04).
d Results at the pre-specified final OS analysis.
e Two-sided p-value based on stratified log-rank test (compared to a significance level of 0.0499).
	LIFYORLI and Nab-Paclitaxel N=188	Nab-Paclitaxel N=193
Progression-free Survival (PFS) by BICR a
Number (%) of patients with events	113 (60)	121 (63)
Median, months (95% CI)	6.5 (5.6, 7.4)	5.5 (3.9, 5.9)
Hazard ratio (95% CI)b	0.70 (0.54, 0.91)
p-valuec	0.0076
Overall Survival (OS)d
Number (%) of patients with events	129 (69)	159 (82)
Median, months (95% CI)	16.0 (13.0, 18.3)	11.9 (10.0, 13.8)
Hazard ratio (95% CI)b	0.65 (0.51, 0.83)
p-valuee	0.0004

Figure 1: Kaplan-Meier Curve for Progression-Free Survival in ROSELLA



Figure 1 (Rel04 0002 02)

Figure 2: Kaplan-Meier Curve for Overall Survival in ROSELLA



Figure 2 (Rel04 0002 03)

Storage and Handling

Store and dispense LIFYORLI in their original carton. Store LIFYORLI at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Advise patients to read the FDA-approved patient labeling (Patient Information).

Principal Display Panel – for 125 mg Outer Carton (1-Dose Supply)

1-Dose Supply:

Contents: One blister card of 2 capsules:

one 100 mg capsules and one 25 mg capsule.

Principal Display Panel (Rel04 0002 04)

Principal Display Panel – for 125 mg Outer Carton (3-Dose Supply)

3-Dose Supply:

Contents: One blister card of 6 capsules:

three 100 mg capsules and three 25 mg capsules.

Principal Display Panel (Rel04 0002 05)

Principal Display Panel – for 125 mg Outer Carton (9-Dose Supply)

9-Dose Supply:

Contents: Three cartons each containing one blister card

of 6 capsules: three 100 mg capsules and three 25 mg capsules.

18 capsules total.

Principal Display Panel (Rel04 0002 06)

Principal Display Panel – for 125 mg Blister Packs (1-Dose Supply)

Principal Display Panel (Rel04 0002 07)

Principal Display Panel – for 125 mg Blister Packs (3-Dose Supply)

Keep out of the reach of children.

See accompanying Patient Information.

Principal Display Panel (Rel04 0002 08)

Principal Display Panel – for 150 mg Outer Carton (1-Dose Supply)

1-Dose Supply:

Contents: One blister card of 3 capsules:

one 100 mg capsules and two 25 mg capsules.

Principal Display Panel (Rel04 0002 09)

Principal Display Panel – for 150 mg Outer Carton (3-Dose Supply)

3-Dose Supply:

Contents: One blister card of 9 capsules:

three 100 mg capsules and six 25 mg capsules.

Principal Display Panel (Rel04 0002 10)

Principal Display Panel – for 150 mg Outer Carton (9-Dose Supply)

9-Dose Supply:

Contents: Three cartons each containing one blister card

of 9 capsules: three 100 mg capsules and six 25 mg capsules.

27 capsules total.

Principal Display Panel (Rel04 0002 11)

Principal Display Panel – for 150 mg Blister Packs (1-Dose Supply)

Principal Display Panel (Rel04 0002 12)

Principal Display Panel – for 150 mg Blister Packs (3-Dose Supply)

Keep out of the reach of children.

See accompanying Patient Information.

Principal Display Panel (Rel04 0002 13)